AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05517980
Drug: KP104
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
Trial: NCT06574126
Drug: Group 1: Dara-VRD followed by apheresis and cilta-cel infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
Trial: NCT06574126
Drug: Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
Trial: NCT06146751
Drug: Superparamagnetic Iron Oxide Nanoparticles
RxNorm normalized name: iron oxide, nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
Trial: NCT05932654
Drug: BSI-045B
RxNorm normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with BSI-045B.
Trial: NCT05551871
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patient will receive Simvastatin for 7 days
Trial: NCT06096870
Drug: PDS01ADC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS01ADC at 12.0 microgram/kg by subcutaneous injection (every 28 days)
Trial: NCT04878627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive placebo for 3 weeks
Trial: NCT06532071
Drug: [68Ga]CBP8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8
Trial: NCT06111586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion at Day 1 and SC Injection from W2 to W102
Trial: NCT05075824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
Trial: NCT05815550
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of PPI defined as PPI mentioned in the safety report
Trial: NCT05280158
Drug: mRNA-1273 (Moderna COVID-19 vaccine)
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
Trial: NCT05924165
Drug: 10mg Ketorolac, Q6 PRN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac is an NSAID used to relieve moderately severe pain.
Trial: NCT06072482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06072482
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
Trial: NCT06174402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/ day
Trial: NCT04681638
Drug: Pathogen-Reduced Plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
Trial: NCT05791565
Drug: Salbutamol HFA-152a
RxNorm normalized name: HYDROFLUOROCARBON 152A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol HFA-152a will be administered.
Trial: NCT05791565
Drug: Salbutamol HFA-134a
RxNorm normalized name: HYDROFLUOROCARBON 134A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol HFA-134a will be administered.
Trial: NCT05081518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - capsule
Trial: NCT06246110
Drug: EIK1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
Trial: NCT05464914
Drug: CEO Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
Trial: NCT06230757
Drug: Placebo (active placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg psilocybin capsule
Trial: NCT06028321
Drug: Part 2 Group G (ACM-001.1)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Trial: NCT06028321
Drug: Part 1 Group 1 Regimen B (Pindolol)
RxNorm normalized name: meningococcal group B vaccine 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
Trial: NCT05689645
Drug: F573 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first stage:the first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg, and the subsequent 9 patients with CHB were given doses of 2.0 mg/kg, with an administration volume of 2 mL and intramuscular injection (IM) according to the efficacy and safety test results of the first 16 patients. The dose was given once a day for 7 days and calculated according to the weight of the last visit.~The second stage:According to the results of Phase I efficacy and safety trials, the dosage was determined to be 0.5 mg/kg and 2.0 mg/kg, the dosage volume was 2 mL, intramuscular injection (IM), once a day for 14 days, and the dosage was calculated according to the weight of the latest visit.~The third stage:The dosage was determined according to the results of the first and second phase efficacy and safety trials. The dosage volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days, and the dosage was calculated according to the weight of the latest .
Trial: NCT04952753
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
Trial: NCT04952753
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
Trial: NCT05980949
Drug: KarXT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
Trial: NCT00044837
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06068478
Drug: Qingzhu Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
Trial: NCT06068478
Drug: Qingzhu Granules Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
Trial: NCT04761770
Drug: conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen
Trial: NCT06096857
Drug: Placebo (sucrose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze dried packet to be reconstituted in water
Trial: NCT05579509
Drug: Midazolam and Fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
Trial: NCT04884490
Drug: Co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
Trial: NCT04884490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo thrice (8 hourly) daily for 7 days orally.
Trial: NCT06435702
Drug: androgen deprivation therapy only
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
Trial: NCT04736199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated tablet matching Darolutamide in appearance, oral administration
Trial: NCT05984745
Drug: Coenzyme Q10 Forte® capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
Trial: NCT06088979
Drug: TOUR006 - 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOUR006 20 MG
Trial: NCT06088979
Drug: TOUR006 - 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOUR006 - 50 MG
Trial: NCT06131983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active treatment by IV infusion
Trial: NCT06179511
Drug: AZD9829
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9829 will be administered by IV infusion
Trial: NCT04826094
Drug: Rehydragel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
Trial: NCT04826094
Drug: Placebo (IM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
Trial: NCT04826094
Drug: Placebo (TCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
Trial: NCT06406400
Drug: AZD4041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7.
Trial: NCT06406400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7.
Trial: NCT05726032
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
Trial: NCT05157126
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid gentamicin administered at the open fracture site
Trial: NCT05157126
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered at the open fracture site
Trial: NCT03943901
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy drug, alkylating agent
Trial: NCT03943901
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy drug, anthracycline antibiotic
Trial: NCT05242315
Drug: Envarsus Oral Product
RxNorm normalized name: Envarsus Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as described in arm/group description
Trial: NCT04671836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
Trial: NCT06188624
Drug: TQB2922 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
Trial: NCT06450197
Drug: AZD7798
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7798
Trial: NCT05248997
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of matching placebo
Trial: NCT06289673
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT as part of Intrathecal triple therapy.
Trial: NCT04838769
Drug: alpha blocker and 5-alpha reductase inhibitor
RxNorm normalized name: 5.alpha.-hydroxy laxogenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
Trial: NCT06542250
Drug: AZD5492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
Trial: NCT05494736
Drug: MK-8527
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8527 capsule taken by mouth.
Trial: NCT06356259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06078592
Drug: BRIDIN-plus Eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRIDIN-plus Eye drops
Trial: NCT06138743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active treatment by IV infusion
Trial: NCT06188520
Drug: AZD8421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK2 inhibitor
Trial: NCT06400472
Drug: LY4170156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT06046859
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
Trial: NCT06046859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
Trial: NCT06360354
Drug: Modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
Trial: NCT05039619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
Trial: NCT05039619
Drug: Acetaminophen/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Trial: NCT06502366
Drug: BDA MDI HFO 160/180 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/albuterol pressurized inhalation suspension, HFO
Trial: NCT06502366
Drug: BDA MDI HFA 160/180 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/albuterol pressurized inhalation suspension, HFA
Trial: NCT06502366
Drug: Placebo MDI HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pressurized inhalation suspension, HFA
Trial: NCT05047263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily, oral
Trial: NCT06548139
Drug: Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
Trial: NCT06548139
Drug: Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
Trial: NCT02254915
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of BCG.
Trial: NCT06500702
Drug: SAR442970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR442970 treatment
Trial: NCT06500702
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo treatment
Trial: NCT06600711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days
Trial: NCT06586515
Drug: LY3962673
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06586515
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT05131971
Drug: GSK3888130B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3888130B will be administered.
Trial: NCT05131971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT04848220
Drug: Temanogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
Trial: NCT04848220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
Trial: NCT06507436
Drug: Herombopag placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Trial: NCT06010758
Drug: Listerine Experimental Mouthwash
RxNorm normalized name: Listerine Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
Trial: NCT06010758
Drug: Listerine Total Care Zero
RxNorm normalized name: Listerine Total Care Zero Alcohol Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
Trial: NCT05803863
Drug: Myatro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myopia control with 0.01% atropine drops